PSMD1 and infection: 1249A8 delivered as a single 4 mg/kg intranasal (i.n.)dose to hamsters 12 hours following infection with SARS-CoV-2 Delta protected them from weight loss, with therapeutic activity further enhanced when combined with 1213H7, an S1-specific neutralizing hmAb.